GlassScriptPhysician profile
Katherine Keller Marcel
NPI 1104288570
$1,169.20
in general payments reported to CMS, 2019-2025
19 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $71.79 · 2021: $22.13 · 2022: $405 · 2023: $259 · 2024: $136 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.67 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.74 | 2023-2025 | Fasenra, Tezspire |
| Teva Pharmaceuticals USA, INC. | $159.41 | 2022-2023 | Ajovy, Austedo |
| Medtronic, INC. | $150.92 | 2025 | Interstim |
| Horizon Therapeutics Plc | $113.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.99 | 2022 | |
| Lilly USA, LLC | $84.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.79 | 2020 | |
| Abbvie INC. | $30.46 | 2023-2024 | |
| Merz North America, INC. | $30.00 | 2020 | |
| Abiomed | $27.78 | 2025 | |
| Azurity Pharmaceuticals, INC. | $25.87 | 2025 | Alvesco |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $24.32 | 2024 | Trelegy Ellipta |
| Blueprint Medicines Corporation | $22.55 | 2023 | Ayvakit |
| Pfizer INC. | $22.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $20.32 | 2025 | Fanapt |
| Organon LLC | $18.08 | 2025 | Vtama |
| Hikma Pharmaceuticals USA | $17.49 | 2024 | Ryaltris |
| Supernus Pharmaceuticals, INC. | $14.25 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Marcel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.